scholarly article | Q13442814 |
P819 | ADS bibcode | 2014PLoSO...997229D |
P356 | DOI | 10.1371/JOURNAL.PONE.0097229 |
P932 | PMC publication ID | 4018276 |
P698 | PubMed publication ID | 24820481 |
P5875 | ResearchGate publication ID | 262265436 |
P50 | author | Hendrik Streeck | Q28032204 |
Margaret E. Ackerman | Q57012155 | ||
Dan H. Barouch | Q60489346 | ||
Galit Alter | Q88683228 | ||
Musie Ghebremichael | Q89849219 | ||
Anne-Sophie Dugast | Q90440217 | ||
P2093 | author name string | Todd J Suscovich | |
Hualin Li | |||
Joseph Nkolola | |||
Ying Chan | |||
Michelle Hoffner | |||
Anna Licht | |||
P2860 | cites work | Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells | Q28270714 |
Antibody neutralization and escape by HIV-1 | Q29547345 | ||
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples | Q30498394 | ||
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers | Q33444658 | ||
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals | Q33526340 | ||
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. | Q33693391 | ||
Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection | Q33834852 | ||
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells | Q33844334 | ||
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge | Q33852768 | ||
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques | Q33966586 | ||
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. | Q34185625 | ||
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. | Q52841139 | ||
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies | Q57226425 | ||
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation | Q57253538 | ||
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression | Q71396764 | ||
Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS | Q78678676 | ||
Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy | Q34647680 | ||
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L | Q35012462 | ||
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals | Q35037803 | ||
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
Control of HIV-1 infection by soluble factors of the immune response | Q35752416 | ||
A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection | Q35876233 | ||
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Q36414891 | ||
Is autoimmunity a component of natural immunity to HIV? | Q36447138 | ||
Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques | Q37033311 | ||
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. | Q37347813 | ||
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose | Q37528015 | ||
The role of antibodies in HIV vaccines | Q37700725 | ||
Fc receptor regulation of protective immunity against Chlamydia trachomatis | Q37872443 | ||
Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques | Q39265150 | ||
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization | Q39723388 | ||
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells | Q40274328 | ||
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. | Q40291422 | ||
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers | Q40659603 | ||
Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients | Q41689302 | ||
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection | Q45740971 | ||
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine | Q45745469 | ||
Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. | Q45987356 | ||
Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | antibody | Q79460 |
P304 | page(s) | e97229 | |
P577 | publication date | 2014-05-12 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies | |
P478 | volume | 9 |
Q35920037 | Animal models in HIV-1 protection and therapy |
Q26991572 | Antibody responses to envelope glycoproteins in HIV-1 infection |
Q59352288 | Antibody-dependent cellular cytotoxicity in HIV infection |
Q37512871 | Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies |
Q34204325 | Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity |
Q89803119 | Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) |
Q26782237 | Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 |
Q58763247 | Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers |
Q40794254 | Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model. |
Q52580309 | First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. |
Q39108716 | HIV antibodies for treatment of HIV infection |
Q36252656 | HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans |
Q52598776 | HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. |
Q35778333 | Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance |
Q64263004 | Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1 |
Q38998925 | Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies |
Q48234349 | Low doses of IgG from atopic individuals can modulate in vitro IFN-γ production by human intra-thymic TCD4 and TCD8 cells: An IVIg comparative approach |
Q64066666 | Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function |
Q38719420 | Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner |
Q64115950 | Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response |
Q90411103 | Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development |
Q40052007 | Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity |
Q52660832 | Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. |
Q37510242 | Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection |
Q91582856 | Neutralization and beyond: Antibodies and HIV-1 acquisition |
Q38748193 | New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. |
Q28068018 | Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization |
Q33638320 | Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. |
Q35569901 | Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life |
Q51743315 | Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges. |
Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
Q35985519 | Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability |
Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
Q37113972 | The role of Fc receptors in HIV prevention and therapy |
Q55411165 | Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. |
Q38764543 | Use of broadly neutralizing antibodies for HIV-1 prevention |
Q50034030 | Virus-Like-Vaccines against HIV. |
Q35641144 | What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure? |
Q40063734 | What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection |